- Home
- GIGM vs MRKR Comparison
GIGM vs MRKR Comparison
Compare GIGM & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GIGM | MRKR |
|---|---|---|
| Founded | 1998 | N/A |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8M | 16.6M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | GIGM | MRKR |
|---|---|---|
| Price | $1.56 | $1.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.25 |
| AVG Volume (30 Days) | 5.5K | ★ 271.0K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,397,000.00 | ★ $4,694,988.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $1.38 | $0.81 |
| 52 Week High | $1.89 | $5.95 |
Technical Indicators
Market Signals| Indicator | GIGM | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 63.24 |
| Support Level | $1.50 | $1.15 |
| Resistance Level | $1.55 | $1.27 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 60.00 | 87.50 |
Price Performance
Historical ComparisonAbout GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.